Minerva Surgical analyst ratings
Minerva Surgical analyst ratings
While ratings are subjective and will change, the latest Minerva Surgical (UTRS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Minerva Surgical (UTRS) is trading at is $2.69, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2022 | — | JP Morgan | Downgrades | Overweight → Underweight | |
| 05/12/2022 | 123.05% | Piper Sandler | $12 → $6 | Maintains | Overweight |
| 05/12/2022 | 160.22% | SVB Leerink | $8 → $7 | Maintains | Outperform |
| 03/09/2022 | 346.1% | Piper Sandler | $17 → $12 | Maintains | Overweight |
| 12/03/2021 | 346.1% | SVB Leerink | $17 → $12 | Maintains | Outperform |
| 11/16/2021 | 531.97% | SVB Leerink | → $17 | Initiates Coverage On | → Outperform |
| 11/16/2021 | 457.62% | UBS | → $15 | Initiates Coverage On | → Buy |
| 11/16/2021 | 420.45% | JP Morgan | → $14 | Initiates Coverage On | → Overweight |
| 11/16/2021 | 531.97% | Piper Sandler | → $17 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/10/2022 | — | 摩根大通 | 降级 | 超重 → 体重不足 | |
| 05/12/2022 | 123.05% | 派珀·桑德勒 | 12 美元 → 6 美元 | 维护 | 超重 |
| 05/12/2022 | 160.22% | SVB Leerink | 8 美元 → 7 美元 | 维护 | 跑赢大盘 |
| 03/09/2022 | 346.1% | 派珀·桑德勒 | 17 美元 → 12 美元 | 维护 | 超重 |
| 2021 年 3 月 12 日 | 346.1% | SVB Leerink | 17 美元 → 12 美元 | 维护 | 跑赢大盘 |
| 11/16/2021 | 531.97% | SVB Leerink | → 17 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 11/16/2021 | 457.62% | 瑞银（UBS） | → 15 美元 | 启动覆盖范围开启 | → 购买 |
| 11/16/2021 | 420.45% | 摩根大通 | → 14 美元 | 启动覆盖范围开启 | → 超重 |
| 11/16/2021 | 531.97% | 派珀·桑德勒 | → 17 美元 | 启动覆盖范围开启 | → 超重 |
Minerva Surgical Questions & Answers
密涅瓦外科问题与解答
The latest price target for Minerva Surgical (NASDAQ: UTRS) was reported by JP Morgan on August 10, 2022. The analyst firm set a price target for $0.00 expecting UTRS to fall to within 12 months (a possible -100.00% downside). 9 analyst firms have reported ratings in the last year.
摩根大通于2022年8月10日公布了密涅瓦外科（纳斯达克股票代码：UTRS）的最新目标股价。该分析公司将目标股价定为0.00美元，预计UTRS将在12个月内降至12个月内（可能下跌-100.00％）。去年有9家分析公司公布了评级。
The latest analyst rating for Minerva Surgical (NASDAQ: UTRS) was provided by JP Morgan, and Minerva Surgical downgraded their underweight rating.
摩根大通对密涅瓦外科（纳斯达克股票代码：UTRS）的最新分析师评级由摩根大通提供，密涅瓦外科下调了减持评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Minerva Surgical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Minerva Surgical was filed on August 10, 2022 so you should expect the next rating to be made available sometime around August 10, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Minerva Surgical的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Minerva Surgical的最新评级是在2022年8月10日提交的，因此您应该预计下一个评级将在2023年8月10日左右公布。
While ratings are subjective and will change, the latest Minerva Surgical (UTRS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Minerva Surgical (UTRS) is trading at is $2.69, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的密涅瓦外科（UTRS）评级已下调，目标股价为0.00美元至0.00美元。Minerva Surgical（UTRS）目前的交易价格为2.69美元，超出了分析师的预期区间。
